Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym

NCT IDNCT06760156ClinicalTrials.gov data as of Apr 2026

Check if I qualify Back to results ClinicalTrials.gov

Phase

Phase 2

Target enrollment

Study length

about 2.9 years

Ages

18+

Locations

1 site in FL

What this study is about

This trial is testing the safety and effectiveness of tafasitamab and lenalidomide in people with Large B-cell Lymphoma (LBCL) after axicabtagene ciloleucel (axi-cel) treatment. Participants will be asked to spend about 12 months in it.

Simplified from trial records by PatientMatch.

What you may be asked to do

1.Take Lenalidomide
2.Take Tafasitamab

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel

In-person visits

Requires travel to a study site

Physical Intervention

Oral

How treatment is administered

Treatment Assignment

All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

lenalidomide (Immunomodulatory drug; affects immune system and cancer cells (exact mechanism unclear)), tafasitamab

Drug routes

oral (Oral Capsule)

Endpoints

Primary: Complete Response Rate (CRR)

Secondary: Duration of Response (DoR), Objectives Response Rate (ORR), Progression Free Survival (PFS)

Screen for this study View on ClinicalTrials.gov